AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02831374 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical extraction of impacted third molar
Description: After achieving Local anesthesia using 2% lignocaine hydrochloride with 1:100,000 epinephrine, standard Terrence Ward's incision was placed to raise a full thickness mucoperiosteal flap. Disto-buccal bone was carefully exposed and bone surrounding the buccal aspect of impacted tooth was performed using surgical bur under copious irrigation with 0.9% saline. Tooth was elevated using Coupland elevator and if required situations tooth was sectioned with surgical bur to facilitate its removal. The socket was checked for any tooth or bony debris. The bony margins smoothened using a file and irrigated with 0.9% saline.
Study NCT02831374 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: surgical extraction of impacted third molar
Description: After achieving Local anesthesia using 2% lignocaine hydrochloride with 1:100,000 epinephrine, standard Terrence Ward's incision was placed to raise a full thickness mucoperiosteal flap. Disto-buccal bone was carefully exposed and bone surrounding the buccal aspect of impacted tooth was performed using surgical bur under copious irrigation with 0.9% saline. Tooth was elevated using Coupland elevator and if required situations tooth was sectioned with surgical bur to facilitate its removal. The socket was checked for any tooth or bony debris. The bony margins smoothened using a file and irrigated with 0.9% saline.
Study NCT02831374 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Preparation of PRP gel
Description: Before surgery, 10 milliliter of venous blood was collected from the anticubital fossa of the patients forearm and stored into sterile tubes containing anticoagulant (0.5 milliliter citrate phosphate dextrose) from each patient in the experimental group using routine venipuncture procedure. The whole blood is then centrifuged at 1,200 rotations per minute for ten minutes. The supernatant layer obtained was platelet poor plasma and buffy coat was collected in a new sterile tube and centrifuged again at 1,000 rotations per minute for 10 min. The upper half of the supernatant is removed and the lower half is mixed carefully to get platelet rich plasma. Five drops of mixture of 10 % CaCl2 and 1000 Units bovine thrombin to 2 milliliter Platelet rich plasma to obtain the gel form.
Study NCT02831374 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placing platelet Rich plasma and suturing
Description: Subsequently, platelet rich plasma gel was placed into the extraction sockets of patients in the group A and wound closure was done using simple interrupted 3.0 black silk sutures.
Study NCT02831374 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Suturing
Description: Wound closure was done using simple interrupted 3.0 black silk sutures.
Study NCT02831374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Postoperative medication
Description: Patients were advised regular post extraction and prescribed 500 milligram of paracetemol postoperatively (1 tablet every 6 hours for 2 days).
Study NCT02831374 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Postoperative medication
Description: Patients were advised regular post extraction and prescribed 500 milligram of paracetemol postoperatively (1 tablet every 6 hours for 2 days).
Study NCT02260531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Study NCT02260531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Study NCT02889692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YiQiFang
Description: Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe.~YiQiFang: Patients with Qi deficiency syndrome are administered two packages of each benefiting Qi and detoxication recipe, four packages, twice a day, until progression or unacceptable.
Study NCT02889692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YangYinFang
Description: Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe.~YangYinFang: Patients with Yin deficiency syndrome are administered two packages of each benefiting Yin and detoxication recipe, four packages, twice a day, until progression or unacceptable.
Study NCT02889692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YiQiYangYinFang
Description: Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe.~YiQiYangYinFang: Patients with Qi and Yin deficiency syndrome are administered one package of each benefiting Qi and benefiting Yin and two packages of detoxication recipe, four packages, twice a day, until progression or unacceptable.
Study NCT02889692 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo granules
Description: Oral granules, which the taste and smell are similar to experimental TCM granules, has no therapeutic effect, four packages, twice a day, until progression or unacceptable.
Study NCT02889692 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Erlotinib®
Description: Erlotinib®,tarceva, 150 mg oral once a day until progression or unacceptable toxicity develops.
Study NCT02889692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib®
Description: Erlotinib®,tarceva, 150 mg oral once a day until progression or unacceptable toxicity develops.
Study NCT02889692 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gefitinib®
Description: Gefitinib®,Iressa, 250 mg oral once a day until progression or unacceptable toxicity develops.
Study NCT02889692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib®
Description: Gefitinib®,Iressa, 250 mg oral once a day until progression or unacceptable toxicity develops.
Study NCT02889692 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Icotinib®
Description: Icotinib®,Conmana 125 mg oral three times a day until progression or unacceptable toxicity develops.
Study NCT02889692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib®
Description: Icotinib®,Conmana 125 mg oral three times a day until progression or unacceptable toxicity develops.
Study NCT01456507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALO-02 (Oxycodone Naltrexone)
Description: single dose of ALO-02 capsule under fasting condition
Study NCT01456507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALO-02 (Oxycodone Naltrexone)
Description: single dose of ALO-02 capsule under fed condition
Study NCT01456507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALO-02 (Oxycodone Naltrexone)
Description: ALO-02 with the ALO-02 pellets sprinkled on applesauce, and administered under fasting conditions.
Study NCT02119169 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pigtail catheter
Description: pigtail catheter for pleural drainage
Study NCT03092024 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SPIN-HAND program
Description: The internet-based SPIN-HAND program consists of 4 modules (1) Thumb Flexibility and Strength (3 exercises); (2) Finger Bending (3 exercises); (3) Finger Extension (3 exercises); and (4) Wrist Flexibility and Strength (2 exercises). The program includes sections on developing a personalized program, goal-setting strategies and examples, progress tracking, sharing goals and progress with friends and family, and patient stories of experiences with hand disability and hand exercises. Instructional videos demonstrate and explain how to perform each exercise properly with pictures to illustrate common mistakes. Separate versions of each exercise are available for patients with mild/moderate and more severe hand involvement.
Study NCT03150160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brinzolamide 1%/brimonidine 0.2% fixed combination
Description: One drop applied topically to the affected eye(s) in the morning and evening
Study NCT03150160 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One drop applied topically to the affected eye(s) in the morning and evening
Study NCT00731042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avagard
Description: Topical solution, 6 mL, 6 applications/day for 14 days.
Study NCT03150160 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: travoprost 0.004% ophthalmic solution
Description: One drop applied topically to the affected eye(s) in the evening
Study NCT03150160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: travoprost 0.004% ophthalmic solution
Description: One drop applied topically to the affected eye(s) in the evening
Study NCT00731042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Purell Surgical Scrub
Description: Topical solution, 4 mL, 6 applications/day for 14 days.
Study NCT04623528 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: T1 and T2 relaxometry of the liver parenchyma
Description: Evaluate T1 and T2 relaxomatry of the liver parenchyma to depict liver congestion in the different patient groups
Study NCT02697799 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-level recruitment strategy consent form
Description: Patients will be exposed to pre-consent messaging and a consent form that includes supplemental information describing a high-level recruitment strategy
Study NCT02697799 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mid-level recruitment strategy consent form
Description: Patients will be exposed to pre-consent messaging and a consent form that includes supplemental information describing a mid-level recruitment strategy
Study NCT04449887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiangsha Liujunzi granules
Description: A traditional Chinese medicine compound, taken three times a day, one bag at a time, for a total of 28 days
Study NCT01875835 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience™ V stent (Abbott Vascular, Santa Clara, California, USA)
Study NCT01875835 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multilink-Vision stent(Abbott Vascular, Santa Clara, California, USA)
Study NCT04156477 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone ester
Description: Intake of weight adjusted drink of a ketone ester
Study NCT04156477 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: Isocaloric and - volumetric taste adjusted drink
Study NCT03722108 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Regorafenib and Irinotecan
Description: Irinotecan (180 mg/m² on D1 and D15 of a 4-week cycle) combined with regorafenib (160 mg daily on D2-8 and D16-22 of a 4-week cycle) administered until progression of disease or unacceptable toxicity
Study NCT04156477 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Tap water
Description: Isovolumetric taste adjusted tap water (placebo)
Study NCT03998878 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate Diet
Description: Participants will be instructed to follow a low-carbohydrate diet.
Study NCT03998878 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent Energy Restriction
Description: Participants will be instructed to follow intermittent energy restriction.
Study NCT03998878 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hunger Training
Description: Participants will be instructed to follow Hunger Training.
Study NCT01545258 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Physiotherapy supervised exercise training. 60 minutes 3 times per week
Study NCT04951440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrate ketone oxazine
Description: Intervention group: 30min intravenous point. Drop qiu was given 1400 mg of injected sichuan nitrone I bed, and the drug was given 100 mL at day F Set 12 h, and at odds with another 7 days, that is, about 14 times in total.
Study NCT04951440 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitrate ketone oxazine
Description: Intervention group: 30min intravenous point. Drop qiu was given 1400 mg of injected sichuan nitrone I bed, and the drug was given 100 mL at day F Set 12 h, and at odds with another 7 days, that is, about 14 times in total.
Study NCT02367131 — intervention group
Intervention type: DRUG
Intervention: JARDIANCE®
Description: JARDIANCE®
Study NCT03708848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Proton pump inhibitor
Study NCT03708848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth Potassium Citrate
Description: Gastric mucosal protective drug with anti-H. pylori effect
Study NCT03722108 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Irinotecan (180 mg/m² on D1 and D15 of a 4-week cycle) administered until progression of disease or unacceptable toxicity
Study NCT00587249 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Malaria ICC-1132
Description: ICC-1132, a candidate malaria vaccine, with alhydrogel will be in 2 ml glass vials containing ICC-1132 at either 40 mcg/ml or 100 mcg/ml concentration formulated with alhydrogel at 1mg/ml. Each vial will contain approximately 0.8 ml solution to permit recovery of 0.5 ml for injection. When shaken, the solution is off-white to greyish-white turbid liquid free of foreign particulate matter.
Study NCT03374072 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Siblings FORWARD program
Description: Siblings will participate in a program developed by the researchers designed to engage adults with their autistic sibling and other family members to plan for the future. The Siblings FORWARD program will be implemented by community service providers already working with autistic adults. The program will involve a series individual and joint sessions with siblings and autistic adults using Zoom.
Study NCT03374072 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information Only Condition
Description: Siblings will be provided with online information about services for adults with ASD and future planning.
Study NCT00611637 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMV pp65 Specific T Cells
Description: Donor derived CMV pp65 specific T cells (1 x 105 CD3+ cells/kg (maximum 1 x 107 CD3+ cells) will be infused into recipient over 10 minutes.
Study NCT03708848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: antibiotic for H. pylori eradication
Study NCT03708848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: antibiotic for H. pylori eradication
Study NCT03708848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: antibiotic for H. pylori eradication
Study NCT03708848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracycline
Description: antibiotic for H. pylori eradication
Study NCT01677546 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CSII+BC+CL
Description: Insulin pump bolus calculator wirelessly communicated with blood glucose meter (Contour Link)
Study NCT01677546 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CSII+BC
Description: Insulin pump bolus calculator without wireless communication with blood glucose meter (Contour Link)
Study NCT03852004 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ostheopathy
Description: standardized osteopathic treatment
Study NCT03852004 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: simulated osteopathic treatment
Description: standardized simulated osteopathic treatment
Study NCT04343300 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates
Description: Intervention of12 weeks of Pilates
Study NCT04343300 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: exercise without Pilates
Description: exercise without Pilates
Study NCT00587249 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alhydrogel
Description: Aluminum hydroxide gel.
Study NCT00736957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol Hydrochloride (HCL) plus Acetaminophen (JNS013)
Description: Tramadol hydrochloride 37.5 milligram (mg) plus acetaminophen 325 mg (JNS013) one or two tablets will be given orally four times daily (maximum dose is 8 tablets per day) for 4 weeks during treatment period 1 (restrictions on concomitant treatments will be established) and for 48 weeks during treatment period 2 (permitting modifications to the concomitant drugs/therapies). The dosing interval will be of at least 4 hours.
Study NCT02372370 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microneedle pretreatment + MAL-PDT
Description: Interventions: microneedling of the skin using dermarollers prior to topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)). Three settings are applied: mild, moderate and strong.
Study NCT03395587 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous, tumor lysate-loaded, mature dendritic cells (DC)
Description: Advanced therapy medicinal product (ATMP) produced at the University Hospital Düsseldorf according to Good Manufacturing Practice (GMP) with production permission according §13 AMG (German Drug Law) of the local authorities (Bezirks¬regierung Düsseldorf)
Study NCT02088333 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mCRC intervention
Description: a multilevel intervention consisting of tablet-based patient education about CRC screening, post-visit patient electronic messaging, and clinic protocols to facilitate ordering of screening tests
Study NCT02372370 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sandpaper pretreatment + MAL-PDT
Description: Interventions: abrasion of the skin using Abrasive Pads for Skin Preparation prior to topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)). Three settings are applied: mild, moderate and strong.
Study NCT02088333 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Healthy Lifestyles video
Description: a brief video about healthy lifestyle habits displayed on a tablet device
Study NCT01618487 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic tenotomy
Description: This is a surgical procedure where small incisions are made and a scope is used to see the tendon and release it.
Study NCT01618487 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open tenotomy
Description: This involves opening the skin on the arm up to expose the muscle and tendon. There is a total of 1 incision made.
Study NCT01618487 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Debridement and repair
Description: This involves using an arthroscopic technique (using a scope and a small incision) to go in and remove any tissue that is diseased/does not belong and repairing the tear(s) in the tendon. There is a total of 1-2 incisions made.
Study NCT04478526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors)
Description: If never taken SSRI or SNRI, commence primary medication arm (SSRI: sertraline, escitalopram or Pregabalin/SNRI: duloxetine, venlafaxine) will be described to patient and will begin either. If deemed unresponsive to either prior to study, commence medication they have not been previously unresponsive to. Unresponsive if GAD did not improve after treatment with maximum tolerated dose for 8-weeks. If deemed unresponsive to SSRI and SNRI/pregabalin, commence secondary medication arm (bupropion/mirtazepine, buspirone/imipramine) with both being described to patient and begin either. Switch protocol: If unresponsive after 4 or 6 weeks, switch to another class. If started in primary or secondary and not previously demonstrated non-response to second class of medications within arm, switch to second class within arm. If started in primary and previously deemed unresponsive to second class, begin secondary if non-response indicates switch necessary.
Study NCT04478526 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic Cognitive Behavioural Therapy
Description: Weekly sessions of e-CBT through OPTT will consist of approximately 30 slides. Each session is expected to last approximately 50 minutes. The content and format of each weekly online session was designed to mirror live CBT. The slides will highlight a different topic each week and include general information, an overview of skills and homework on that topic. The homework included in each session will be submitted through OPTT and reviewed by the clinicians with personalized feedback provided by clinicians within three days of submission. Weekly homework submission for feedback will be mandatory before being eligible for the next session. Biweekly GAD-7, DASS-42 and Q-LES-SF questionnaires will be completed through OPTT. A second STAI will be completed in the final week of e-CBT treatment.
Study NCT02710240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green (ICG)